

Company Overview

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Mar 13 2024, 4:26 PM EDT

Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments

Feb 1 2024, 8:30 AM EST

ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE

Dec 15 2023, 4:20 PM EST

Stock Overview Investor Relations

Symbol ENZ IR@enzo.com Exchange NYSE

Market Cap 55.84m
Last Price \$1.09
52-Week Range \$1.07 - \$2.74

04/19/2024 04:00 PM EDT

Management Team

Patricia Eckert, CPA

Chief Financial Officer

Kara Cannon

Chief Executive Officer

Enzo Biochem, Inc.

81 Executive Blvd Suite 3 Farmingdale, NY 11735

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.